Over the course of this extensive timeline, advances in perinatal medicine have revolutionized the prognosis for infants born severely premature, defined typically as those delivered before 32 weeks of gestation. The study meticulously charts the incremental improvements in neonatal survival, revealing a trajectory influenced not only by enhanced technologies but also by evolving clinical practices and the integration of evidence-based medicine. Researchers leveraged a robust dataset drawn from a single tertiary care center renowned for its neonatal intensive care unit (NICU), thereby controlling for variability often introduced by multi-institutional studies.

The first waves of data in the late 1970s set a stark baseline: mortality among very preterm neonates was alarmingly high, reflecting the state of neonatal medicine at the time. During this era, respiratory distress syndrome (RDS) was a primary cause of death, and supportive measures were limited. The advent and subsequent widespread adoption of antenatal corticosteroids in the 1980s marked a pivotal turning point, significantly reducing the incidence and severity of RDS. This intervention, coupled with improvements in mechanical ventilation strategies, created a foundation for enhanced survival.

By examining decade-spanning cohorts, the researchers noted not only survival improvements but also shifts in the causes of neonatal mortality. Later years saw declines in infection-related deaths as aseptic techniques, antibiotic stewardship, and early diagnosis improved. Additionally, advances in nutritional support, specifically parenteral nutrition and human milk feeding protocols, appeared to correlate with better growth and immune function, further bolstering survival odds.

Crucially, the study addresses the impact of evolving NICU technology, including the introduction of less invasive ventilation modalities, surfactant replacement therapy, and continuous monitoring systems. These technologies, introduced progressively through the 1990s and 2000s, facilitated more individualized, gentle respiratory support, mitigating potential harms associated with earlier ventilatory methods. Additionally, the researchers emphasize the role of collaborative care models, where multidisciplinary teams comprising neonatologists, nurses, respiratory therapists, and other specialists coordinate care, enhancing overall outcomes.

A notable focus of this study lies in the demographic and socioeconomic factors influencing neonatal mortality. The Dallas cohort provided an ethnically and socioeconomically diverse patient population, enabling analyses of disparities and identification of at-risk groups. While overall mortality declined, disparities persisted, prompting calls for targeted interventions aimed at equity in neonatal outcomes. This aspect underscores the inextricability of clinical advancements and social determinants of health in shaping neonatal survival.

The study also examines trends in neurodevelopmental outcomes, an essential complement to mortality data. As more preterm neonates survive, the emphasis shifts towards ensuring quality of life and reducing long-term disability. The authors discuss the integration of early intervention programs, developmental follow-ups, and family-centered care approaches that have evolved in parallel with survival improvements.

Importantly, this longitudinal analysis does not shy away from discussing periods of plateau and even regression, where survival gains temporarily stabilized or reversed. These fluctuations reflect challenges such as new pathogen emergence, resource constraints, and healthcare policy shifts. Such findings highlight the necessity for sustained vigilance, continuous quality improvement initiatives, and adaptability in neonatal care practices.

From a methodological perspective, this single-institution cohort study benefits from consistency in data capturing, patient management protocols, and institutional policies over time, lending credibility to its conclusions. However, the authors acknowledge limitations, including changing definitions of viability, differences in prenatal care access, and broader healthcare system transformations that may influence comparability across eras.

Looking forward, the study implicates several promising avenues for further improvement in outcomes for very preterm neonates. Enhanced precision medicine approaches, leveraging genomic and biomarker data, hold potential in tailoring interventions. Moreover, advances in telemedicine and digital health could expand access to specialized neonatal care in underserved regions, possibly reducing geographic disparities observed in this study.

The findings from this detailed 47-year review prompt healthcare policymakers and neonatal care professionals to reflect on the iterative nature of medical progress. The journey from high mortality rates in the late 20th century to the significantly improved outcomes today is a testament to multidisciplinary innovation, resource investment, and the resiliency of clinical teams. Equally, the persistent disparities and occasional setbacks serve as a call to action to ensure that every preterm infant benefits equitably from scientific advancements.

In conclusion, this landmark cohort analysis from Dallas offers invaluable insights into how far neonatal medicine has come and the complex interplay of medical, technological, and social factors shaping outcomes. As neonatal care continues to evolve, ongoing research, investment in equitable healthcare delivery, and relentless innovation will remain vital in securing the survival and well-being of the most vulnerable newborns in society.

Subject of Research: Changes in mortality among very preterm neonates over several decades at a single healthcare institution in Dallas, Texas.

Article Title: Changes in mortality in very preterm neonates in a single institution in Dallas, Texas, 1977–2024: a cohort study.

Article References:
Brion, L.P., Rosenfeld, C.R., Burchfield, P.J. et al. Changes in mortality in very preterm neonates in a single institution in Dallas, Texas, 1977–2024: a cohort study. Pediatr Res (2026). https://doi.org/10.1038/s41390-026-05106-0

Image Credits: AI Generated

DOI: 23 May 2026

Neonatal jaundice, characterized by elevated bilirubin levels leading to yellowing of the skin and eyes, poses significant risks if left inadequately treated. Standard phototherapy uses specific wavelengths of blue light to breakdown bilirubin molecules, facilitating their removal from the infant’s system. Historically, this therapy requires prolonged hospitalization, imposing not only financial strain on families and healthcare systems but also psychological and logistical burdens on parents. The advent of portable phototherapy devices has prompted healthcare professionals to reconsider home treatment protocols, aiming to maintain therapeutic outcomes while mitigating hospital dependency.

The study’s comprehensive methodology incorporated data from extensive clinical trials and economic analyses, providing evidence-based insights into the comparative advantages of home phototherapy. One of the critical findings highlights that home phototherapy can achieve similar clinical efficacy in reducing bilirubin levels when administered with proper guidance and monitoring. This equates to decreased hospital admissions and shorter inpatient durations, effectively lowering healthcare costs without compromising treatment quality. Importantly, the underlying technology involves light-emitting diode (LED) devices optimized for home use, which pose minimal risks and ensure sufficient irradiance to attain therapeutic goals.

Healthcare economists participating in this study provided detailed cost-benefit analyses, accounting for direct medical expenses, parental work absence, and long-term implications of hospital stays including risk of nosocomial infections. The researchers emphasize that home phototherapy, by facilitating treatments in familiar environments, significantly reduces indirect costs associated with hospital care. Additionally, the psychological comfort gained by both infants and parents during home treatment cannot be overstated. The findings suggest a paradigm shift, where healthcare policy might prioritize integrating home-based interventions into standard neonatal care pathways.

Technological advancements in phototherapy units serve as a cornerstone for this transition. Devices designed for home use are equipped with sensors ensuring appropriate light intensity and timers controlling exposure duration, thereby enhancing treatment adherence and safety. These innovations, combined with telemedicine platforms for remote monitoring, allow clinicians to oversee patient progress without physical visits. Such integration represents a growing trend toward digital transformation in healthcare, blending device engineering with data analytics to optimize patient outcomes while preserving clinical oversight.

Despite these promising developments, the study acknowledges challenges that warrant further investigation. Ensuring equitable access to home phototherapy devices and training for diverse socioeconomic groups is paramount to prevent healthcare disparities. The researchers call for standardized protocols and regulatory frameworks facilitating the safe distribution and use of home units. Moreover, the role of health insurance coverage in subsidizing these devices plays a critical role in widespread adoption, underscoring the intersection of medical innovations with healthcare policy and economics.

Parental education emerged as a vital component in the success of home phototherapy. The study details structured training programs that caregivers undergo, designed to ensure proper device application, recognition of complications, and adherence to treatment schedules. This education not only enhances the safety and effectiveness of therapy but also empowers parents, fostering a collaborative healthcare environment. In the context of patient-centered care, such empowerment is closely linked with improved health outcomes and satisfaction.

The implications extend beyond individual families to the broader healthcare system. The study presents predictive modeling indicating the potential relief on neonatal intensive care units (NICUs) by adopting home phototherapy protocols. With hospital infrastructures often strained by increasing admissions, a decentralized model of care for conditions like neonatal jaundice could redistribute resources toward more acute cases. This strategic resource allocation could optimize hospital workflows and reduce systemic bottlenecks, ultimately translating into better healthcare service delivery at scale.

Concurrently, the psychosocial ramifications for families coping with hospitalization and neonatal illness receive focused attention. The researchers discuss how home phototherapy alleviates stress associated with hospital separation and exposure to clinical environments. This reduction in anxiety enhances parental mental health during a critical period, potentially influencing bonding and breastfeeding success, both pivotal for neonatal development. The ripple effects of these psychosocial benefits contribute to holistic improvements in neonatal care paradigms.

From a global health perspective, the study underscores the adaptability of home phototherapy in low-resource settings. Considering the scarcity of hospital beds and the high costs of extended inpatient care in many developing regions, portable phototherapy offers a scalable solution. The affordability and logistical feasibility of home treatment resonate with global public health goals aimed at reducing neonatal morbidity and mortality. Yet, the authors underscore the necessity of context-specific adaptations, such as power supply reliability and community healthcare support, to ensure efficacy across diverse environments.

Importantly, the publication also touches on the environmental benefits of home-based care. Hospitals, with their intensive energy consumption and waste generation, contribute significantly to healthcare-related carbon footprints. Home phototherapy reduces hospital stays, lowering demand for energy-intensive infrastructure usage. Coupled with the energy-efficient designs of modern phototherapy devices, this shift illustrates a convergence between clinical innovation and sustainability efforts, an increasingly essential consideration in healthcare advancements.

Clinicians expressed cautious optimism about integrating home phototherapy, balancing enthusiasm with the need for rigorous clinical governance. The study highlights ongoing research into optimizing patient selection criteria to identify neonates most suitable for home treatment, ensuring uncompromised safety profiles. Adverse event monitoring remains pivotal, demanding robust communication channels between families and healthcare providers to swiftly address complications. The authors advocate for continued clinical trials and longitudinal studies to refine protocols and validate long-term outcomes.

Furthermore, the ethical dimensions of delegating complex treatments to non-professional caregivers receive thoughtful discussion. While home phototherapy demonstrates promise as a safe and effective alternative, it changes traditional dynamics of medical responsibility. The study encourages establishing clear guidelines delineating healthcare provider accountability while empowering parents, safeguarding both patient welfare and caregiver well-being. This delicate balance epitomizes the evolving interface between medical science and societal norms.

In conclusion, this comprehensive study charts a visionary path toward optimizing neonatal jaundice management through home phototherapy. By harnessing technological innovation, economic evaluation, and patient-centered care principles, the findings articulate a compelling case for reimagining treatment delivery paradigms. As healthcare systems worldwide grapple with increasing demands and cost pressures, this research signals an auspicious future where accessible, efficient, and compassionate care converges in the home environment, heralding transformative impacts on neonatal health outcomes globally.

Subject of Research:
Cost-effectiveness and clinical evaluation of home-based phototherapy for neonatal jaundice.

Article Title:
Opinions on the cost-effectiveness of home phototherapy.

Article References:
Pettersson, M., Ryen, L., Eriksson, M. et al. Opinions on the cost-effectiveness of home phototherapy. Pediatr Res (2025). https://doi.org/10.1038/s41390-025-04658-x

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41390-025-04658-x

The study approaches a pivotal clinical dilemma: how to balance the undeniable benefits of empirical antibiotic therapy against the potentially detrimental effects of prolonged exposure. Prolonged antibiotic use in neonates is associated with adverse outcomes, including antibiotic resistance, disruption of the developing microbiome, and increased risk for necrotizing enterocolitis. In light of these risks, the indiscriminate or excessively prolonged administration of antibiotics can paradoxically cause harm. Yet premature cessation might lead to undertreatment of a potentially fatal infection. The meticulous nature of the review by Feng and colleagues underscores the variability in clinical practice and attempts to resolve one of neonatology’s most frustrating grey zones.

This comprehensive meta-analysis synthesizes data drawn from a broad spectrum of randomized controlled trials, cohort studies, and observational data sets that explore various empirical antibiotic discontinuation strategies in neonates suspected of EOS. The researchers evaluated parameters such as duration of empirical antibiotic therapy, timing based on clinical and laboratory findings, and the impact of discontinuation timing on outcome measures like mortality, reinfection, and adverse events. Through rigorous methodological frameworks, the study achieved an unprecedented examination of safety and efficacy, providing an invaluable resource for healthcare providers navigating this delicate therapeutic decision.

A cornerstone of the analysis presented by Feng et al. is the nuanced differentiation between neonates at low and high risk for EOS. The authors meticulously dissect how discontinuation strategies must be tailored, reflecting the heterogeneity of neonatal populations. In low-risk neonates, characterized by reassuring clinical presentations and negative blood cultures, premature discontinuation of antibiotics often poses minimal risk and significantly curtails unnecessary exposure. Conversely, in high-risk infants, often those born prematurely or with prolonged rupture of membranes, the evidence suggests a more cautious approach. The meta-analysis quantifies these subtleties, anchoring guidelines in stratified risk assessments rather than broad, one-size-fits-all recommendations.

Technological advancements in rapid diagnostic assays, such as molecular blood culture techniques and biomarker analyses — notably procalcitonin and C-reactive protein levels — also found significant attention in the study. The incorporation of these diagnostics allowed the authors to highlight the evolving role of timely and accurate laboratory results in guiding antibiotic discontinuation decisions. Data demonstrate that integrating biomarker trends with clinical observations can safely shorten antibiotic courses without compromising outcomes. This heralds a paradigm shift from purely empiric decision-making toward a precision medicine approach that refines treatment duration based on dynamic clinical and laboratory profiles.

One of the study’s most compelling revelations is the apparent safety of discontinuing empirical antibiotics within 48 to 72 hours in neonates who exhibit negative culture results and favorable clinical progress. This finding challenges the entrenched clinical dogma that often mandates longer antibiotic courses “just in case,” especially when isolated pathogen identification remains elusive due to the limitations of culture-based diagnostics. By systematically evaluating large patient cohorts, Feng and colleagues paint a reproducible picture wherein a shorter, evidence-based discontinuation timeline is not only achievable but also recommended to avert the collateral damage of overtreatment.

However, the authors caution that blanket policy endorsements must be tempered by acknowledgment of local epidemiological variations, hospital capabilities, and patient population differences. The meta-analysis spans diverse geographic regions and healthcare infrastructures, thereby reinforcing that antibiotic stewardship strategies must be contextually adapted. For example, settings with high prevalence of multidrug-resistant organisms or limited access to rapid diagnostics may still warrant more conservative approaches to discontinuation. This demographic and infrastructural nuance renders the study’s conclusions both universally relevant and pragmatically measured.

The review further discusses critical adverse outcomes associated with inappropriate discontinuation timing, including treatment failure, infection relapse, and prolonged hospital stay. By quantifying these risks, the authors offer clinicians concrete data supporting vigilance but also the imperative to avoid unnecessary antibiotic exposure. The data accentuate the importance of continuous clinical reassessment coupled with iterative evaluation of laboratory markers as guiding principles underpinning safe discontinuation.

Importantly, Feng et al. integrate emerging data on the long-term consequences of early antibiotic exposure on neonatal gut microbiota development. The disruption of this delicate microbial ecosystem has been associated with increased risks of allergic, metabolic, and neurodevelopmental disorders later in life. This dimension of the analysis highlights how decisions made within the first critical days of life have ripple effects that extend well beyond the neonatal period, underscoring the need for antibiotic prudence rooted in robust evidence.

The systematic review and meta-analysis also delve into policy implications, advocating for harmonization of existing guidelines with contemporary evidence. The authors propose a coherent framework for empirical antibiotic discontinuation that aligns with modern diagnostic capabilities and stratified risk models. Such harmonization could standardize care, reduce variability, and ultimately improve neonatal outcomes globally. Their call to action is a clear signal for multidisciplinary collaboration among neonatologists, infectious disease experts, microbiologists, and policymakers.

Furthermore, the paper sheds light on the challenges posed by ongoing clinical uncertainty and the ethical considerations in enrolling critically ill neonates in randomized trials. The authors argue for the importance of high-quality prospective studies focused on discontinuation timing, to enrich this evidence base and continually refine practice standards. They also emphasize the critical role of educational initiatives aimed at multidisciplinary teams to ensure evidence uptake and translation into bedside decision-making.

Another salient point emerging from the review is the evaluation of antibiotic stewardship programs tailored for neonatal units. The authors illustrate how multidisciplinary stewardship interventions significantly reduce empirical antibiotic duration without compromising safety. These programs typically combine protocolized discontinuation algorithms, real-time diagnostic feedback, and continuous staff education, demonstrating measurable benefits in both resource utilization and clinical outcomes.

Feng and colleagues also contextualize their findings within the broader framework of antimicrobial resistance, a global health threat exacerbated by overuse of antibiotics in all populations including neonates. Their review reiterates that neonatal antibiotic policies are not confined to individual patient safety, but intertwine with stewardship imperatives that preserve antibiotic efficacy for future generations. This dual focus enriches the public health relevance of their conclusions.

The meta-analysis thoroughly addresses potential limitations, including publication bias, heterogeneity across studies, and variations in defining EOS and discontinuation criteria. The authors transparently discuss these factors and employ sensitivity analyses to affirm the robustness of their conclusions. This rigorous appraisal strengthens the credibility and applicability of the findings.

In conclusion, this landmark study by Feng, Zhang, and Hua offers a timely and technically sophisticated evaluation of empirical antibiotic discontinuation in suspected neonatal EOS. The balance of evidence supports earlier, evidence-based cessation protocols, nuanced by clinical risk stratification and supported by advanced diagnostics. The work stands poised to reshape neonatal care protocols, reduce unwarranted antibiotic exposure, and improve both short- and long-term outcomes for vulnerable newborns. As neonatal units worldwide grapple with the dual imperatives of saving lives and safeguarding future health, this research provides a beacon of clarity and hope.

Subject of Research: Discontinuation strategies for empirical antibiotics in suspected neonatal early-onset sepsis (EOS).

Article Title: Discontinuation of empirical antibiotics in suspected neonatal early-onset sepsis: a systematic review and meta-analysis.

Article References:
Feng, K., Zhang, T. & Hua, Z. Discontinuation of empirical antibiotics in suspected neonatal early-onset sepsis: a systematic review and meta-analysis. Pediatr Res (2025). https://doi.org/10.1038/s41390-025-04290-9

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41390-025-04290-9

Thrombocytopenia, defined as a platelet count below 150,000 per microliter, frequently complicates the clinical picture of preterm neonates due to their immature hematopoietic systems and exposure to various perinatal insults. These low platelet counts predispose infants to hemorrhagic complications, making timely intervention critical. Historically, platelet transfusion thresholds were set conservatively high, often around 50,000 to 100,000 platelets per microliter, out of an abundance of caution. This approach was based on the assumption that higher platelet counts would directly correlate with decreased bleeding risk and better clinical outcomes. However, the medical community has increasingly questioned whether such aggressive strategies inadvertently expose neonates to risks associated with transfusions themselves.

The risks linked to platelet transfusions are multifaceted. Beyond the immediate procedural risks—such as transfusion reactions and volume overload—there is growing recognition of transfusion-associated immunomodulation, which can alter immune responses and potentially increase susceptibility to infections and inflammatory conditions. Additionally, the scarcity and cost of platelet products and regulatory concerns about donor compatibility underscore the importance of judicious use. The new investigative efforts led by Lalos and colleagues sought to harmonize transfusion practice by establishing evidence-based, restrictive platelet transfusion thresholds to reduce unnecessary transfusions without compromising neonatal safety.

To accomplish this, the team conducted a rigorous, multi-phased project within a high-acuity NICU setting. Their approach commenced with a comprehensive review of existing guidelines and literature, revealing substantial variations in clinical practice and an absence of universally accepted transfusion criteria. Recognizing that protocol heterogeneity could contribute to disparate outcomes, the researchers designed a standardized guideline that carefully calibrated transfusion thresholds, balancing bleeding risk against the dangers of overtransfusion. This guideline introduced lower platelet count thresholds for transfusion initiation with carefully stratified decision points aligned to clinical variables such as the infant’s gestational age, clinical stability, and presence of active bleeding or invasive procedures.

Implementation of the restrictive guideline was accompanied by extensive staff education and multidisciplinary collaboration, ensuring that neonatologists, hematologists, nurses, and transfusion specialists shared a unified understanding of the rationale and operational framework. Over the course of several months, data were meticulously collected on transfusion frequency, neonatal clinical outcomes, and any adverse events. The results were striking: restrictive thresholds led to a substantial decrease in the number of platelet transfusions administered without increasing the incidence of clinically significant bleeding episodes. In fact, the reduction in transfusions was linked with a decrease in transfusion-related complications, shedding light on the double-edged sword the practice had long represented.

The implications of this shift extend beyond the immediate NICU environment. By reducing transfusion exposure, the guideline may contribute to diminished healthcare costs, conserved blood product resources, and improved long-term health trajectories for preterm neonates. The study also argues for harmonization across neonatal units to foster improved comparability of outcomes and facilitate broader adoption of best practices. Its findings challenge entrenched dogma, powerfully advocating for a more nuanced understanding of thrombocytopenia management that prioritizes both safety and efficacy.

The clinical significance of this research cannot be overstated. It underscores the criticality of grounded clinical decision-making informed by robust data rather than tradition or untested assumptions. Neonatal thrombocytopenia, once treated under a model of maximal prophylaxis, now beckons a sophisticated approach that appreciates the complexity of platelet physiology, the intricate interplay of neonatal hemostasis, and the unintended consequences of overtransfusion. The nuanced strategy borne out by Lalos and teams invites clinicians worldwide to re-evaluate thresholds and protocols, potentially resetting the standard of care.

In addition to the direct clinical benefits, this work shines a light on the importance of guideline-driven transfusion medicine as a pillar of neonatal safety. In an era where personalized medicine and precision care are gaining momentum, the study demonstrates how even incremental tweaks—rooted in evidence and executed collaboratively—can catalyze transformative improvements in patient outcomes. The standardization of transfusion practices also speaks to broader healthcare imperatives of quality assurance and risk mitigation within the dynamic context of neonatal intensive care.

From a physiological perspective, the study underscores the delicate balance between platelet counts and hemostatic competence in newborns whose clotting systems differ markedly from adults. Preterm infants possess functional differences in platelet adhesion, aggregation, and coagulation factor activity that influence bleeding risks independently of platelet numbers alone. Thus, rigid transfusion triggers based solely on numerical thresholds may fail to capture the individualized bleeding risk or resilience of each neonate. The restrictive approach proposed embraces this complexity, integrating clinical judgment rather than rigid lab cutoffs as the cornerstone of management.

Furthermore, the research addresses a critical gap in evidence-based neonatal transfusion practices. Past guidelines were often extrapolated from adult data or informed by expert consensus rather than rigorous clinical trials. The new work by Lalos and colleagues bridges this gap by presenting a validated, prospectively implemented protocol, which can serve as a foundational reference for future clinical trials. It invites ongoing scrutiny, refinement, and validation across diverse neonatal populations and practices, stimulating a much-needed discourse on the optimal integration of transfusions in neonatal care pathways.

The intricate coordination and interdisciplinary effort required to enact and evaluate this new policy reveal the complexity inherent in modern NICU care. It is not solely a matter of altering transfusion thresholds but requires institutional commitment, continued education, and data-driven quality improvement mechanisms. The study’s success also highlights a progressive clinical culture that embraces evidence over inertia, carefully balancing innovation with patient safety amidst the inherent vulnerabilities of the neonatal population.

Critically, the study’s data reinforce the notion that more transfusions do not equate to better outcomes. This challenges clinicians to deeply interrogate the underpinnings of their clinical heuristics and to consider the full spectrum of risks and benefits associated with transfusions. The concept of “doing less” in medicine is often counterintuitive but can yield profound benefits when grounded in science. By shifting toward restrictive transfusion practices, neonatal teams may mitigate avoidable iatrogenic harm and foster improved survival and developmental outcomes in preterm infants.

Looking forward, the pioneering work by Lalos et al. sets a robust platform for ongoing research into biomarkers and individualized risk stratification strategies that could further refine transfusion triggers. Advances in neonatal hemostasis monitoring, platelet function assays, and emerging technologies may one day enable truly personalized transfusion medicine in NICUs, where decisions transcend static numerical counts to embrace dynamic physiological insights.

In conclusion, the development and implementation of restrictive platelet transfusion thresholds represent a seismic advancement in neonatal thrombocytopenia management. It moves the field beyond conservative, risk-averse dogma toward a more sophisticated, evidence-led approach that prioritizes both efficacy and safety. This transformative research underscores the profound impact that carefully crafted clinical guidelines can have on patient care, resource utilization, and healthcare outcomes in some of the most vulnerable patients. The study by Lalos, Brumfiel, Viehl, and collaborators is poised to reshape transfusion practices across neonatal units worldwide, offering a new beacon of hope in the complex fight against thrombocytopenia in preterm neonates.

Subject of Research: Management of thrombocytopenia in preterm neonates through development and implementation of restrictive platelet transfusion thresholds.

Article Title: Development and implementation of restrictive platelet transfusion thresholds in a neonatal intensive care unit.

Article References:
Lalos, N., Brumfiel, A., Viehl, L.T. et al. Development and implementation of restrictive platelet transfusion thresholds in a neonatal intensive care unit. J Perinatol (2025). https://doi.org/10.1038/s41372-025-02302-4

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41372-025-02302-4